<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        32-355-05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALEXAN 1000MG- 20ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CYTARABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        103.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cytarabine, the active substance in Alexan, inhibits cell division and therefore the growth of cancer cells.</p><p>&nbsp;</p><p>Alexan is a medication used to treat various types of cancer (leukaemia, lymphomas).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Alexan</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to cytarabine or any of the other ingredients of this medication listed under Section 6</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of reduced production of blood cells in bone marrow (myelosuppression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of severely reduced renal and/or hepatic function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of existing severe infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of stomach and intestinal ulcers and recent operations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of anaemia (erythrocytopaenia), leukopaenia (white blood cell deficiency) and/or thrombocytopaenia (platelet deficiency)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently being treated or have received treatment for chickenpox or shingles (herpes zoster) with brivudine, sorivudine or their analogues in the last 4 weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during lactation</p><p>&nbsp;</p><p><strong>Warnings and Precautions</strong></p><p>Speak to your doctor or pharmacist before using Alexan. If you take phenytoin against epileptic seizures, you should be examined regularly due to potentially elevated phenytoin plasma levels. Simultaneous use of phenytoin and Alexan can intensify the effect of phenytoin.</p><p>&nbsp;</p><p>Alexan must only be used with caution in specialised facilities with appropriate possibilities for regular monitoring of the effects during and after administration.</p><p>Alexan inhibits the production of blood cells in bone marrow (myelosuppression). After discontinuing the medication, the number of blood cells may continue to decrease. The number of blood cells should be checked regularly, even after the end of therapy, and a bone marrow examination should be conducted if required.</p><p>Caution should be exercised with patients with drug-induced myelosuppression in their medical history.</p><p>&nbsp;</p><p>Alexan can cause increased uric acid levels in the blood due to the destruction of cancer cells. The uric acid content in the blood should therefore be monitored. Your doctor will inform you about the need to take medications to control your uric acid level.</p><p>&nbsp;</p><p>Special caution is required with mild reduction of hepatic and renal function.</p><p>&nbsp;</p><p>Reduced liver and kidney function is considered a predisposing factor for increased CNS toxicity due to Alexan.</p><p>&nbsp;</p><p>Since Alexan is mainly broken down in the liver, a stronger effect of the substance is possible in users with liver damage. An increase in efficacy also results in reduced renal function. In the case of reduced liver and/or kidney function, a corresponding dose reduction must be performed while blood levels are monitored. Regular monitoring of liver and kidney function as well as uric acid levels is necessary. In patients with preexisting reduced liver function, cytarabine should be administered with caution and after a strict risk-benefit assessment, particularly with high doses.</p><p>&nbsp;</p><p>Ensure that you drink enough fluids.</p><p>&nbsp;</p><p>Anaphylactic reactions may occur during treatment with Alexan, especially immediately after intravenous administration.</p><p>&nbsp;</p><p>High-dose treatment with Alexan in patients over 60 years of age may only take place after a particularly careful risk-benefit assessment.</p><p><strong>&nbsp;</strong></p><p><u>Birth Control Measures:</u></p><p>Alexan can change the genetic material. Men should therefore not father children during treatment and for up to six months after ending treatment. In addition, you should receive information before treatment regarding the option of sperm preservation, since there is the possibility of infertility (sterility) after Alexan therapy.</p><p>&nbsp;</p><p>A genetic consultation is recommended if women wish to have children after the end of treatment.</p><p>&nbsp;</p><p>Severe gastrointestinal side effects require antiemetic (for nausea) and other supportive measures.</p><p>&nbsp;</p><p>High dosage treatments require regular monitoring of the central nervous system function and the lung function by a specialist.</p><p>&nbsp;</p><p>In order to avoid eye problems, they must be rinsed regularly during high dosage treatment.</p><p>&nbsp;</p><p>During therapy with Alexan, no vaccinations with live vaccines should be administered.</p><p>&nbsp;</p><p>Treatment with Alexan involves the risk of bleeding complications and severe infections.</p><p>During high-dose therapy, disorders of the central nervous system, the gastrointestinal tract, the liver, as well as skin reactions and eye symptoms may occur.</p><p>&nbsp;</p><p>Contact with the skin, mucous membranes and eyes must be avoided.</p><p>&nbsp;</p><p>Simultaneous use of Alexan with other medications may cause acute inflammation of the pancreas.</p><p>&nbsp;</p><p>Cases of severe neurological side effects that range from headache to paralysis, coma, and stroke-like episodes have been mainly observed in children and adolescents who received intravenous Alexan in combination with intrathecal methotrexate.</p><p>&nbsp;</p><p>Cytarabine, the active substance of Alexan, is a substance that can harm your unborn child and change the genetic material.</p><p>&nbsp;</p><p><strong>Use of Alexan with Other Medications</strong></p><p>Inform your doctor or pharmacist if you are taking/using other medications, have recently taken/used other medications or intend to take/use any other medications.</p><p>&nbsp;</p><p>Concomitant use of certain antiviral (used to treat viruses) medications such as sorivudine, brivudine, or their derivatives, may significantly intensify the side effects of Alexan (see the Section &ldquo;Do Not Use Alexan&rdquo;).</p><p>&nbsp;</p><p>You must exercise particular caution if you take medications against epileptic seizures (phenytoin). Simultaneous use of phenytoin and Alexan can intensify the effect of phenytoin. Your doctor will regularly monitor your phenytoin plasma level.</p><p>&nbsp;</p><p>Simultaneous or prior therapy with cell-damaging substances or radiation therapy may intensify the myelosuppression caused by Alexan.</p><p>&nbsp;</p><p>Alexan may cause acute pancreatitis in case of previous treatment with L-asparaginase (medication used to treat blood cancer).</p><p>&nbsp;</p><p>Interactions are to be expected when combining different cytostatics (medication used to treat cancer).</p><p>&nbsp;</p><p>5-fluorocytosin should not be administered with Alexan, as it has been shown that the effect of 5-fluorocytosin (medication to treat fungal infections) can be inhibited by Alexan.</p><p>&nbsp;</p><p>In patients who also receive digoxin (medication used to treat heart failure), digoxin levels in the blood must be monitored during Alexan therapy since a reduction in blood levels and therefore an impaired effect of digoxin may occur. Since this is not the case with digitoxin, a switch from digoxin to digitoxin is advisable for patients receiving cytarabine therapy.</p><p>&nbsp;</p><p>In laboratory studies, Alexan appears to reduce the susceptibility of some bacteria (K. pneumoniae) to the antibiotic gentamicin. If there is no response to gentamicin, your doctor will switch antibiotics if necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, Breastfeeding and Fertility</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medication.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>In some animal species, malformations occurred in the use of cytarabine on the foetus. The use of cytarabine in women who are pregnant or could become pregnant may only be carried out after careful consideration of the possible risks and benefits.</p><p>&nbsp;</p><p>If you become pregnant during treatment with Alexan, please notify your doctor immediately.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Do not breastfeed during treatment with Alexan. Breastfeeding must be stopped before the start of treatment with Alexan.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Alexan may be mutagenic. This means that the medication may cause genetic mutations. Alexan may impair sperm and egg production, which is associated with the possibility of birth defects.</p><p>During treatment with Alexan and at least during the first 6 months after the end of treatment, you must avoid conceiving a child. Since treatment with Alexan can lead to infertility, it may be advisable for male patients to consider sperm preservation before the start of treatment (see also the Section &ldquo;Warnings and Precautions&rdquo;).</p><p>&nbsp;</p><p><strong>Driving and Operating Machinery</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Symbol: Achtung" style='width:30.75pt;height:27pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title=" Achtung"/>
</v:shape><![endif]--><img width="41" height="36" alt="Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" />&nbsp;&nbsp;&nbsp; Caution: This medication may affect the ability to react and impair the ability to &nbsp; drive.</p><p>&nbsp;</p><p><strong>Alexan contains sodium</strong></p><p>This medication contains less than 1 mmol (23 mg) of sodium per ml, i.e. it is virtually &ldquo;sodium-free&rdquo;.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alexan therapy may only be used by doctors with special training and experience in the field of cancer therapy. This therapy should be initiated in hospital.</p><p>&nbsp;</p><p>For intravenous (in a vein) and intrathecal (in the cerebrospinal fluid) or subcutaneous (in the subcutaneous fatty tissue) administration.</p><p>You will receive Alexan either as an infusion into a vein (intravenous), as an injection into the cerebrospinal fluid or occasionally as an injection into the subcutaneous fatty tissue (subcutaneous).</p><p>&nbsp;</p><p>Information for the Physician: For information on dosage, see the prescribing information or treatment protocols in the specialist literature.</p><p>&nbsp;</p><p><strong>If you receive more Alexan than you should</strong></p><p>Your doctor will ensure that you receive the correct dose for your disease. In the event of an overdose, increased side effects may occur. Your doctor will then discontinue the therapy and, if required, treat any side effect symptoms and initiate supportive measures.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medication, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medications, this medication can cause adverse reactions, though they will not occur in every person being treated with Alexan.</p><p>&nbsp;</p><p>The side effects caused by Alexan depend on the dosage, method of administration and treatment duration.</p><p>&nbsp;</p><p>Local tolerance is generally high. Sometimes inflammation may occur at the injection site.</p><p>&nbsp;</p><p>The evaluation of adverse reactions is based on the following frequencies:</p><p>Very common (may affect more than 1 in 10 persons treated)</p><p>Common (may affect up to 1 in 10 persons treated)</p><p>Uncommon (may affect up to 1 in 100 persons treated)</p><p>Rare (may affect up to 1 in 1,000 persons treated)</p><p>Very rare (may affect up to 1 in 10,000 persons treated)</p><p>Unknown (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood poisoning (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lungs (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone marrow failure disorders, changes in blood count (e.g. white or red blood cell or platelet deficiency, abnormal blood cells); are dosage-dependent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis (in case of high dosage therapy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced liver function, hyperbilirubinaemia (increased levels of the bile pigment bilirubin) have been observed in 25&ndash;50% of patients receiving high dosage treatment.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, increased uric acid levels in the blood. Hypocalcaemia may also occur (calcium deficiency in the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallowing difficulties</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation or ulcers in the mouth or anus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea, nausea and vomiting (especially after rapid intravenous injection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions (redness, ulceration, skin rash, hives), vascular inflammation, mottled skin, itching. After high doses, exfoliative dermatitis (inflammation of the skin with blistering and peeling skin) and hair loss may occur.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cerebral disorders (eye tremor, speech disorders, movement disorders, confusion and personality changes), thought and movement disorders, dizziness, impaired consciousness with increased stimulation threshold, coma, trembling, seizures and loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis, inflammation of the cornea, light sensitivity, burning eyes, severe lacrimation and vision disorders are dosage-dependent and were observed in 25&ndash;80% of patients undergoing high dosage therapy. (The symptoms may be prevented or mitigated with frequent eye rinses or prophylactic use of corticosteroid eye drops.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary disorders, renal impairment. An increase in plasma creatinine (metabolite) has been observed in 5 to 20% of patients receiving high-dose cytarabine therapy, but a confirmed causal connection with cytarabine has not been proven. Measures to prevent uric acid nephropathy should be taken in the case of massive cell degeneration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throat inflammation, allergic oedema (water accumulation), disordered production of sex hormones, sperm and ovum cells, pain in the chest area, ascites (water accumulation in the abdominal cavity), weakened immune system, sepsis (blood poisoning), thrombophlebitis (inflammation and occlusion of the veins) and bleeding. Fever occurs in 20&ndash;50% of patients undergoing high dosage therapy.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation or ulcers in the oesophagus, severe mucous membrane changes in the gastrointestinal tract with ulceration, destruction and perforation of the intestinal wall (necrosis), intestinal obstruction, peritonitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brown/black pigment spots on the skin (lentigo), ulcers on the skin, itching, burning pain on the palms and soles of the feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disease of the peripheral nerves (peripheral neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain and/or joint pain were observed after high doses of Alexan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems, shortness of breath, sore throat, pulmonary oedema (fluid accumulation in the lungs, can be cured in most cases), pneumonia (diffuse interstitial pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute pericardial inflammation</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intrathecal (injection into the cerebrospinal fluid) use of Alexan may cause nausea, vomiting and fever</p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the perspiratory glands</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isolated cases of pathological changes in white brain matter (necrotising leucoencephalopathy), damage to the spinal cord with symptoms of paralysis that affect the limbs (para- and quadriplegia) and blindness have been described after administration of Alexan into the cerebrospinal fluid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occurrence of rhabdomyolysis (breakdown of muscle fibres) has been described.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlargement of the liver. There are individual reports of the occlusion of blood vessels that drain the liver (Budd-Chiari syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart muscle damage, temporary cardiac arrhythmia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (hives, allergic shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The syndrome of inadequate antidiuretic hormone secretion has been observed in individual cases in patients receiving high dosage treatment with Alexan.</p><p>&nbsp;</p><p><strong>Unknown</strong> (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cellulitis (inflammation of the deep layers of skin) at the injection site, liver abscess</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hand-foot syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, headache, inflammation of the nerves and, after high doses, individual cases of peripheral nerve damage have been described, as well as cases of paralysis, meningitis and encephalitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate</p><p>&nbsp;</p><p><u>Alexan (Ara-C) syndrome</u></p><p>This syndrome described in the literature is characterised by fever, muscle pain, bone pain, occasionally chest pain, skin rash with blistering, conjunctivitis and nausea. It generally occurs 6&ndash;12 hours after administration. Corticosteroids (anti-inflammatory agent) have been proved to be successful in the treatment or prevention of the syndrome. If corticosteroids are effective in this regard, continuation of treatment with Alexan may be considered.</p><p>&nbsp;</p><p>With a high dosage prolonged infusion, the side effects are more pronounced than in standard therapy.</p><p>Cases of early death were reported as a result of myelosuppression.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 25&deg;C.</p><p>Store in the original packaging in order to protect from light.</p><p>&nbsp;</p><p>Keep this medication out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medication past the expiry date indicated on the outer packaging or on the label after &ldquo;Use by&rdquo;. The expiry date refers to the last day of the month specified.</p><p>&nbsp;</p><p>For single use only. Dispose of any unused product.</p><p>&nbsp;</p><p><u>Solution for infusion after dilution</u></p><p>&nbsp;</p><p>The chemical and physical stability of the ready-for-use preparation when diluted with 0.9% sodium chloride has been demonstrated at 2&deg;C to 8&deg;C for 28 days.</p><p>&nbsp;</p><p>From a microbiological point of view, the reconstituted preparation should be used immediately. If the reconstituted preparation is not used immediately, the user is responsible for the duration and conditions of storage. If the ready-to-use solution is not prepared under controlled and validated aseptic conditions, it should not be stored for longer than 24&nbsp;hours at 2&deg;C to 8&deg;C.</p><p>&nbsp;</p><p>After use, dispose of the bottle and injection materials (including gloves) according to the regulations for cytostatics. Any unused product as well as the primary packaging must be disposed of as hazardous waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is cytarabine.</p><p>1 ml contains 50 mg cytarabine in stabilised, aqueous solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are: sodium lactate solution 60%, lactic acid, water for injections,</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, colourless injection/infusion solution
pH value: 7.5–9.3


For 50 mg/ml:
1/5/10 x 10 ml vials
1/5/10 x 20 ml vials
1/5/10 x 40 ml vials

Glass vials with/without transparent plastic containers (Onco-Safe).
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Marketing Authorization Holder</p><p>EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria</p><p>&nbsp;</p><p>Manufacturer</p><p>Fareva Unterach GmbH, 4866 Unterach, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ـJuly 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">تثبط مادة سيتارابين، وهي المادة الفعَّالة الموجودة في عقار أليكسان، انقسام الخلية؛ وبالتَّالي فهي تثبط نمو الخلايا السرطانية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار أليكسان هو دواء يُستخدَم لعلاج أنواع مختلفة من السرطان (سرطان الدَّم، سرطان الغدد الليمفاوية).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong>&nbsp;ت<strong>ستخدم عقار أليكسان في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سيتارابين أو تجاه أي مكون من المكونات الأخرى الموجودة بهذا الدَّواء المدرجة أسفل القسم: 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة انخفاض إنتاج خلايا الدَّم في النخاع العظمي (كبت النخاع العظمي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بقصور شديد في وظائف الكُلى و/أو الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بعدوى شديدة قائمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بقُرَح في المعدة والأمعاء والخضوع لعمليات جراحية حديثًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بفقر الدَّم (قلَّة كرَيَّات الدَّم الحمراء) و/أو قلَّة كرَيَّات الدَّم البيْضاء و/أو نقص الصَّفائح الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالج حاليًّا أو قد تلقيت علاجًا للجُدري المائي أو الهربس النطاقي باستخدام بريفودين أو سوريفودين أو نظائرهما خلال الأسابيع الأربعة الأخيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء الرضاعة الطبيعيَّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام عقار أليكسان. إذا كنت تتناول فينيتوين لعلاج نوبات الصرع، ينبغي عليك الخضوع للفحص بصفة منتظمة بسبب احتمالية ارتفاع مستويات فينيتوين بالبلازما. قد يؤدي استخدام فينيتوين بالتَّزامن مع عقار أليكسان إلى زيادة حدة تأثير فينيتوين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام عقار أليكسان فقط مع توخي الحذر، ويتم ذلك في منشآت متخصصة ذات إمكانيات مناسبة تسمح بمراقبة الآثار بصفة منتظمة أثناء تلقي العقار وبعد تلقيه.</p><p dir="RTL">يثبط عقار أليكسان إنتاج خلايا الدَّم في النخاع العظمي (كبت النخاع العظمي). بعد التوقف عن تلقي الدَّواء، قد يستمر عدد خلايا الدَّم في الانخفاض. يجب التحقق من عدد خلايا الدَّم بصفة منتظمة، حتى بعد نهاية العلاج، كما يجب إجراء فحص للنخاع العظمي إذا لزم الأمر.</p><p dir="RTL">يجب توخي الحذر في المرضى الذين لديهم تاريخ مَرَضي من التعرُّض لكبت النخاع العظمي المحفز بواسطة العقار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُؤدي عقار أليكسان إلى ارتفاع مستويات حمض اليوريك في الدَّم نتيجة تدمير الخلايا السرطانية. لذلك، يجب مراقبة محتوى حمض اليوريك في الدَّم. سيبلغك طبيبك بضرورة تناوُل الأدوية لضبط مستوى حمض اليوريك لديك بالدّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي حذر خاص مع القصور الطفيف في وظائف الكبد والكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعتَبَر قصور وظائف الكبد والكُلى أحد العوامل المهيئة لزيادة تسمم الجهاز العصبي المركزي نتيجة العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا إلى أن عقار أليكسان يتم تكسيره في الكبد بشكل أساسي، فمن المُمكِن أن يكون للمادة تأثير أقوى في المستخدمين الذين لديهم تلف بالكبد. تؤدي أيضًا الزيادة في الفعَّالية إلى الإصابة بقصور في وظائف الكُلى. في حال حدوث قصور في وظائف الكبد و/أو الكُلى، يجب إجراء خفض مماثل للجرعة أثناء فحص مستويات العقار في الدَّم. من الضروري إجراء مراقبة منتظمة لوظائف الكبد والكُلى فضلًا عن مستويات حمض اليوريك. في المرضى المُصابين بحالة قائمة بالفعل من قصور وظائف الكبد، يجب استخدام سيتارابين بحذر وبعد تقييم صارم للفوائد مقابل المخاطر لا سيَّما عند استخدامه بجرعات مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكَّد من شرب كميات كافية من السَّوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث تفاعلات تأقية أثناء العلاج بعقار أليكسان لا سيَّما فور إعطائه عن طريق الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم علاج المرضى ممن تزيد أعمارهم عن 60 عامًا بجرعة مرتفعة من عقار أليكسان فقط بعد إجراء تقييم دقيق بشكل خاص للفوائد مقابل المخاطر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>تدابير منع الحَمْل</u><u>:</u></p><p dir="RTL">يُمكِن أن يُغيِّر عقار أليكسان من طبيعة المادة الوراثية. لذلك، يجب على الرجال تجنُّب إحداث الحمل أثناء العلاج ولمدة تصل إلى ستة أشهر بعد إنهاء العلاج. بالإضافة إلى ذلك، يجب عليك الحصول على معلومات قبل العلاج بشأن خيار الاحتفاظ بالحيوانات المنوية؛ ذلك لأنه من المُمكِن حدوث عُقْم بعد العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى بالاستشارة بشأن الأمور الوراثية إذا كانت السيدات ترغب في الإنجاب بعد نهاية العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتطلب الآثار الجانبية الشديدة التي تصيب الجهاز الهضمي علاجًا مضادًّا للقيء (لعلاج الغثيان) واتخاذ تدابير أخرى داعمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتطلب العلاجات باستخدام جرعة مرتفعة إجراء مراقبة منتظمة لوظائف الجهاز العصبي المركزي ووظائف الرئة من جانب طبيب متخصص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لتجنُّب حدوث مشاكل في العين، يجب شطف العينين بصفة منتظمة أثناء العلاج باستخدام جرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم تلقي أي تطعيمات بلقاحات حية أثناء العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينطوي العلاج بعقار أليكسان على احتمالية التعرُّض لخطر حدوث مضاعفات نزفية وعدوى شديدة.</p><p dir="RTL">قد تحدث اضطرابات في الجهاز العصبي المركزي والجهاز الهضمي والكبد، فضلًا عن حدوث تفاعلات جلدية وأعراض في العين أثناء العلاج باستخدام جرعة مرتفعة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تجنُّب ملامسة العقار للجلد والأغشية المخاطية والعينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي استخدام عقار أليكسان بالتَّزامن مع أدوية أخرى إلى حدوث التهاب حاد في البنكرياس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ حدوث حالات من الإصابة بآثار جانبية متعلقة بالجهاز العصبي تراوحت بين الصداع إلى الشلل والغيبوبة ونوبات شبيهة بنوبات السكتة الدماغية بشكل أساسي في الأطفال والمراهقين الذين تلقوا عقار أليكسان عن طريق الوريد بمصاحبة ميثوتريكسات داخل القراب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتارابين، المادة الفعَّالة لعقار أليكسان، هي مادة قد تُلحِق ضررًا بجنينك كما قد تُغيِّر من طبيعة المادة الوراثية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار أليكسان مع الأدوية الأخرى</strong></p><p dir="RTL">أبلِغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول/تستخدم أدوية أخرى أو تناولت/استخدمت مؤخرًا أدوية أخرى أو تنوي تناوُل/استخدام أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي الاستخدام المُتزامِن لبعض الأدوية المضادة للفيروسات (التي تُستَخدَم للعلاج من الفيروسات) مثل: سوريفودين أو بريفودين أو مشتقاتهما إلى زيادة حدة الآثار الجانبية لعقار أليكسان بشكلٍ ملحوظ (انظر قسم: &quot;لا تستخدم عقار أليكسان في الحالات الآتية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك توخي حذر خاص إذا كنت تتناول أدوية لعلاج نوبات الصرع (فينيتوين). قد يؤدي استخدام فينيتوين بالتَّزامن مع عقار أليكسان إلى زيادة حدة تأثير فينيتوين. سيراقب طبيبك مستوى فينيتوين لديك في البلازما بصفة منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي العلاج المُتزامِن أو العلاج السابق بمواد مُتلِفة للخلايا أو بالعلاج الإشعاعي إلى زيادة حدة تثبيط النخاع العظمي بفعل عقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي عقار أليكسان إلى حدوث التهاب حاد بالبنكرياس في حالة العلاج السابق بعقار إل- أسباراجيناز (دواء يُستَخدَم لعلاج سرطان الدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُتوَقَّع حدوث تداخلات دوائية عند الجمع بين مثبطات نمو الخلايا المختلفة (أدوية تُستَخدَم لعلاج السرطان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ألا يُستَخدَم 5-فلوروسيتوزين بمصاحبة عقار أليكسان، فقد تبين أن عقار أليكسان من المُمكِن أن يثبط تأثير 5-فلوروسيتوزين (دواء يُستَخدَم لعلاج العدوى الفطرية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في المرضى الذين يتلقون أيضًا ديجوكسين (دواء يُستَخدَم لعلاج فشل القلب)، يجب مراقبة مستويات ديجوكسين في الدَّم أثناء العلاج بعقار أليكسان؛ ذلك لأنه قد يحدث انخفاض في مستويات ديجوكسين في الدَّم وبالتَّالي يضعف تأثيره. نظرًا لعدم انطباق ما سبق على العلاج بديجيتوكسين، فيُنصح المرضى الذين يتلقون علاجًا بسيتارابين الانتقال من العلاج بديجوكسين إلى العلاج بديجيتوكسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفقًا للدراسات المعملية التي أُجريت، تبين أن عقار أليكسان يخفض حساسية بعض البكتيريا (الكلبسيلة الرئوية) تجاه المضاد الحيوي جنتاميسين. إذا لم تكن هناك استجابة تجاه جنتاميسين، فسيغير طبيبك المضاد الحيوي إذا اقتضى الأمر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ قبل تلقي هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">في بعض فصائل الحيوانات، حدثت تشوُّهات في الأجنة عند استخدام سيتارابين. ينبغي ألا تستخدم السيدات الحوامل أو اللاتي يمكن أن يصبحن حوامل سيتارابين إلا بعد التَّمَعُّن جيدًا في المخاطر والفوائد المُحتَمَلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ إخطار طبيبكِ فورًا إذا أصبحتِ حاملًا أثناء العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تمارسي الرضاعة الطبيعية أثناء العلاج بعقار أليكسان. يجب التوقف عن ممارسة الرضاعة الطبيعية قبل بدء العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">من المُمكِن أن يكون لعقار أليكسان تأثير مُطَفِّر. وهذا يعني أنَّ الدّواء قد يُسبب طفرات وراثية. قد يُضعف عقار أليكسان إنتاج الحيوانات المنوية والبويضات، وهو أمر يُصاحِبه إمكانية حدوث عيوب خلقية.</p><p dir="RTL">يجب تجنب الإنجاب أثناء العلاج بعقار أليكسان وخلال الأشهر الستة الأولى على الأقل بعد نهاية العلاج. نظرًا إلى أن العلاج بعقار أليكسان قد يُؤدي إلى حدوث العقم، فقد يكون من المُسْتَحْسَن للمرضى من الذكور وضع حفظ الحيوانات المنوية بعين الاعتبار قبل بدء العلاج (انظر أيضًا قسم: &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Symbol: Achtung" style='width:30.75pt;height:27pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title=" Achtung"/>
</v:shape><![endif]--><img width="41" height="36" alt="Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" />&nbsp;&nbsp;&nbsp; تنبيه: قد يؤثر هذا الدّواء على القدرة على الاستجابة، ويُضعف القدرة على &nbsp; القيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار أليكسان على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدّواء على أقل من 1 مللي مول (23 مجم) من الصوديوم لكل مللي لتر، أي: إنه &quot;خالٍ من الصوديوم&quot; تقريبًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يقتصر استخدام العلاج بعقار أليكسان على الأطباء ممن تلقوا تدريبًا خاصًّا ولديهم خبرة في مجال علاج السرطان. يجب بدء هذا العلاج في المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا العقار مُخصص للاستخدام عن طريق الوريد وداخل القراب (في السائل الدماغي النخاعي) أو تحت الجلد (في النسيج الدهني تحت الجلد).</p><p dir="RTL">ستتلقى عقار أليكسان إما في هيئة تسريب وريدي أو في هيئة حَقْن في السائل الدماغي النخاعي أو أحيانًا في هيئة حَقْن في النسيج الدهني أسفل الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات للطبيب: للاطلاع على معلومات حول الجرعة، انظر المعلومات الوصفية أو بروتوكولات العلاج الواردة في النَّشرة المُوَجَّهة للأخصائيين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تلقيت كمية أكبر مما يجب من عقار أليكسان</strong></p><p dir="RTL">سيتأكَّد طبيبك من أنك قد تلقيت الجرعة الصحيحة لحالتك المَرَضيّة. في حال تلقي جرعة زائدة، قد تحدث آثار جانبية متزايدة. حينها سيوقف طبيبك العلاج، وإذا لزم الأمر سيتولى علاج الأعراض الناجمة عن حدوث أي أثر جانبي، وسيبدأ في اتخاذ التَّدابير الدَّاعمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاتصل بطبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يسبب هذا الدّواء آثارًا جانبية إلا أنها لن تحدث لدى كل شخص يُعالج بعقار أليكسان.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">تعتمد الآثار الجانبية الناجمة عن عقار أليكسان على الجرعة وطريقة الاستخدام ومدة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد التحمُّل الموضعي مرتفعًا بشكل عام. قد يحدث أحيانًا التهاب في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستند تقييم الآثار الجانبية على معدّلات التكرار التَّالية:</p><p dir="RTL">شائعة جدًّا (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص خاضعين للعلاج)</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص خاضعين للعلاج)</p><p dir="RTL">غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص خاضع للعلاج)</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص خاضع للعلاج)</p><p dir="RTL">نادرة جدًّا (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص خاضع للعلاج)</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص خاضعين للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي (تعفن الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالعدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات فشل النخاع العظمي، تغيُّرات في عدد خلايا الدَّم (على سبيل المثال: نقص خلايا الدَّم البيضاء أو الحمراء أو الصفائح الدَّموية، اضطراب خلايا الدَّم)؛ ويعتمد ذلك على الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المُلْتَحِمَة (في حالة الخضوع للعلاج بجرعة مرتفعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ حدوث قصور في وظائف الكبد، فَرْط البِيلِيروبين بالدَّم (ارتفاع مستويات الصبغة الموجودة في العصارة الصفراوية &quot;البيليروبين&quot;) في 25-50٪ من المرضى الذين يتلقون العلاج بجرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص خاضعين للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، ارتفاع مستويات حمض اليوريك في الدَّم. قد يحدث أيضًا نقص في مستوى الكالسيوم بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو قُرَح بالفم أو الشرج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد، غثيان وقيء (لا سيَّما بعد الحَقْن الوريدي السريع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية (احمرار، تقرُّح، طفح جلدي، شرى [أرتكاريا])، التهاب الأوعية الدَّموية، بقع بالجلد، حكة. بعد تلقي جرعات مرتفعة، قد يحدث التهاب الجلد التقشري (التهاب الجلد مع ظهور بثور وتقشر بالجلد) وتساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالدماغ (ارتعاش بالعين واضطرابات بالكلام واضطرابات بالحركة وارتباك وتغيُّرات في الشخصية)، اضطرابات في الأفكار والحركة، دوخة، ضعف الوعي مع ارتفاع عتبة التَّحفيز، غيبوبة، ارتجاف، نوبات تشنُّجية وفقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ حدوث التهاب بالمُلْتَحِمَة، التهاب بالقرنية، حساسية تجاه الضوء، حُرقة بالعينين، إدماع شديد واضطرابات في الرؤية في 25-80٪ من المرضى الذين يخضعون للعلاج بجرعة مرتفعة، وهي أعراض معتمدة على الجرعة. (يُمكِن الوقاية من الأعراض أو تخفيفها عن طريق شطف العين بصفة متكررة أو الاستخدام الوقائي لقطرات العين التي تحتوي على الكورتيكوستيرويدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المسالك البولية، قصور وظائف الكُلى. لوحظ حدوث ارتفاع في مستوى الكرياتينين (مُستَقلَب) في البلازما في 5 إلى 20٪ من المرضى الذين يتلقون علاجًا بجرعة مرتفعة من سيتارابين، ولكن لم يُثبَت وجود علاقة سببية مؤكدة بالعلاج بسيتارابين. ينبغي اتخاذ إجراءات للوقاية من اعتلال الكُلى الناجم عن تراكم حمض اليوريك في حال حدوث انحلال جسيم بالخلايا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحَلْق، وذمة تحسسية (تراكُم الماء)، اضطرابات في إنتاج الهرمونات الجنسية وخلايا الحيوانات المنوية والبويضات، ألم في منطقة الصدر، استسقاء (تراكُم الماء في تجويف البطن)، ضعف الجهاز المناعي، تعفن الدَّم (تسمم دموي)، التهاب الوريد الخثاري (التهاب الأوردة وانسدادها) ونزيف. يُصاب 20-50٪ من المرضى الذين يخضعون للعلاج بجرعة مرتفعة بالحُمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص خاضع للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو قُرَح في المريء، تغيُّرات شديدة في الغشاء المخاطي في الجهاز الهضمي مع حدوث تقرحات، تلف وانثقاب جدار الأمعاء (نخر)، انسداد الأمعاء، الْتِهاب الصِّفاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع صبغية باللون البني/الأسود على الجلد (نمش)، قُرَح على الجلد، حكة، ألم حارق على راحتي اليدين وباطني القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يصيب الأعصاب الطرفية (اعتلال الأعصاب الطرفية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ حدوث ألم عضلي و/أو ألم بالمفاصل بعد تلقي جرعات مرتفعة من عقار أليكسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التَّنَفُّس، ضيق في التَّنَفُّس، التهاب الحَلْق، وذمة رِئَوِيَّة (تراكُم السَّوائل في الرئتين، يُمكِن علاجه في غالبية الحالات)، التهاب رئوي (التهاب رئوي خلالي منتشر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب التأمور الحاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص خاضع للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي استخدام عقار أليكسان داخل القراب (الحَقْن في السائل الدماغي النخاعي) إلى الإصابة بالغثيان والقيء والحُمّى.</p><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص خاضع للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدد العرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرى رصد حالات فردية من حدوث تغيُّرات باثولوجية في المادة البيضاء الموجودة بالمخ (اعتلال ناخر ببيضاء الدماغ)، وتلف بالنخاع الشوكي مصحوب بأعراض شلل تصيب الأطراف (شلل سُفلِي ورباعي) وفقدان البصر، وذلك بعد إعطاء عقار أليكسان في السائل الدماغي النخاعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرى رصد حدوث إصابة بانحلال الربيدات (تحلل الألياف العضلية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَضخُّم الكبد. وردت تقارير فردية بشأن حدوث انسداد بالأوعية الدَّموية التي تعمل على تصريف الدم من الكبد (متلازمة بود-كياري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بعضلة القلب، اضطرابات مؤقتة في النَّظْم القلبي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (شرى [أرتكاريا]، صدمة تحسسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم رصد الإصابة بمتلازمة الإفراز غير المناسب للهرمون المضاد لإدرار البول في حالات فردية من المرضى الذين يتلقون العلاج بعقار أليكسان بجرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب النسيج الخلوي (التهاب الطبقات العميقة من الجلد) في موضع الحَقْن، خراج في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة اليد والقدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرى رصد حالات من الدوخة والصداع والتهاب الأعصاب، وبعد تلقي جرعات مرتفعة، جرى رصد حالات فردية من تلف الأعصاب الطرفية، فضلًا عن حالات من الشلل والتهاب السّحَايَا والتهاب الدماغ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>متلازمة عقار أليكسان </u><u>(</u><u>سيتوزين</u><u>- </u><u>أرابينوسيد</u><u>)</u></p><p dir="RTL">تتمثل خصائص هذه المتلازمة المُوَضَّحة في المواد المنشورة في حدوث حُمّى، ألم في العضلات، ألم في العظام، ألم بالصدر أحيانًا، طفح جلدي مصحوب ببثور، التهاب بالمُلْتَحِمَة وغثيان. وتحدث بشكل عام بعد مرور 6&ndash;12 ساعة من الإعطاء. ثبت نجاح الكورتيكوستيرويدات (أدوية مضادة للالتهاب) في علاج المتلازمة أو الوقاية منها. إذا كانت الكورتيكوستيرويدات فعَّالة في هذا الصدد، فيُمكِن النظر في مواصلة العلاج بعقار أليكسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مع تسريب الجرعات المرتفعة لفترة طويلة، تكون الآثار الجانبية أكثر وضوحًا منها مع العلاج القياسي.</p><p dir="RTL">جرى الإبلاغ عن حالات من الوفاة المبكرة نتيجة كبت النخاع العظمي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">يُحفَظ داخل العبوة الأصلية، للحماية من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تَستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الخارجية أو على المُلصق بعد &quot;يُستخدَم قبل&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المحدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاستخدام مرة واحدة فقط. تَخلّص من أي منتج لم يتم استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المحلول المُعد للتسريب بعد التخفيف</u><u>:</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">أظهر المستحضر الجاهز للاستخدام ثباتًا كيميائيًّا وفيزيائيًّا عند تخفيفه باستخدام كلوريد الصوديوم 0.9٪ في درجة حرارة تتراوح بين درجتين مئويتين و8 درجات مئوية لمدة 28 يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة النَّظر الميكروبيولوجية، يجب استخدام المستحضر المُعَد على الفور. إذا لم يُستَخدَم المستحضر المُعَد على الفور، يتحمل المُستخدِم مسؤولية مدة التَّخزين وظروفه. إذا لم يُحَضَّر المحلول الجاهز للاستخدام في ظل ظروف تعقيم مُضبطة وتم التَّحقق من صحتها، ينبغي عدم تخزينه لمدة تزيد عن 24 ساعة في درجة حرارة تتراوح بين درجتين مئويتين و8 درجات مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الاستخدام، تخلَّص من الزجاجة ومواد الحَقْن (بما في ذلك القفازات) وفقًا للأحكام الخاصة بالتَّخلُّص من مثبطات نمو الخلايا. يجب التَّخلص من أي مُنتَج غير مُستَخدَم فضلًا عن العبوة الرئيسية باعتبارهما نفايات خطرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي سيتارابين.</p><p dir="RTL">يحتوي كل 1 مللي لتر على 50 مجم سيتارابين في محلول مائي مستقر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السواغات الأخرى هي: محلول لاكتات الصوديوم 60٪، حمض اللاكتيك، ماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول حقن/تسريب صافٍ وعديم اللون.</p><p dir="RTL">قيمة درجة الحموضة: 7.5&ndash;9.3</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للتركيز 50 مجم/مللي لتر:</p><p dir="RTL">1/5/10 زجاجات &times; 10 مللي لترات</p><p dir="RTL">1/5/10 زجاجات &times; 20 مللي لترًا</p><p dir="RTL">1/5/10 زجاجات &times; 40 مللي لترًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">زجاجات زجاجية ذات/بدون حاويات بلاستيكية شفافة (Onco-Safe).</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسَّویق</p><p dir="RTL">شركة إيبيفيه فارما المحدودة ، 4866 أونتراخ، النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">جھة التصَّنیع<br />شركة فاریفا أونتراخ المحدودة<br />٤۸٦٦ أونتراخ، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alexan 20 mg/ml – vial
Alexan 50 mg/ml – vial

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alexan 20 mg/ml – vial:
1 ml contains 20 mg cytarabine in stabilised, aqueous solution

Alexan 50 mg/ml – vial:
1 ml contains 50 mg cytarabine in stabilised, aqueous solution

For the full list of excipients, see Section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injection/infusion solution

Colourless, clear solution.
pH value: 7.5–9.3



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alexan is indicated in adults.</p><p>&nbsp;</p><p><u>1. Standard Treatment:</u></p><p>Alexan is a cytostatic drug for induction therapy of clinical remission and/or maintenance therapy in patients with</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute non-lymphoblastic leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute lymphoblastic leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute myeloid leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse histiocytic lymphoma (non-Hodgkin&rsquo;s lymphoma with high malignancy).</p><p><em>&nbsp;</em></p><p><u>2. High dosage cytarabine therapy</u><em> </em>is indicated in patients with:</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; refractory acute non-lymphoblastic leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; refractory acute lymphoblastic leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blast flare-up in chronic myeloid leukaemia,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leukaemia with special risk, such as acute leukaemia in the form of secondary malignancy after prior chemotherapy and/or radiation,</p><p><!--[if supportFields]><span lang=DE
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'>SYMBOL 183 \f &quot;Symbol&quot; \s 12 \h</span><![endif]--><!--[if supportFields]><span
lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; refractory non-Hodgkin&rsquo;s lymphoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dosage</strong></p><p>Treatment with Alexan is to be initiated by or under the supervision of a physician experienced in treatment with cytostatics.</p><p>It must be assumed that effective plasma levels are between 0.01 and 0.15 mg/ml. The dose must be determined individually, preferably corresponding to body surface area (BSA).</p><p>&nbsp;</p><p>Alexan is used in combination with other cytostatic substances within the framework of complex therapy protocols.</p><p>Only general dosing recommendations can be given. The exact dosage can be found in treatment protocols in the specific specialist literature.</p><p>&nbsp;</p><p><u>Patients with reduced hepatic or renal function</u></p><p>In patients with reduced hepatic or renal function, this medicinal product should be used with caution and the dosage may need to be reduced as necessary (see also Section 4.4).</p><p>&nbsp;</p><p><u>Elderly Patients</u></p><p>In patients &gt;60 years of age, high dosage therapy should only be performed after a careful risk-benefit analysis.</p><p><u>&nbsp;</u></p><p><u>Standard Dosage</u></p><p>a)&nbsp;&nbsp;&nbsp; <u>Induction Therapy in Case of Acute Leukaemia</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IV injection of 100&ndash;200 mg/m&sup2; BSA/day</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IV infusion of 100 mg/m&sup2; BSA/day</p><p>&nbsp;</p><p>The aforementioned doses are a guideline and must be adapted to the respective therapy regimen.</p><p>&nbsp;</p><p>The duration of treatment depends on clinical and morphological findings (bone marrow). Either the patient can be treated for up to 7 days, followed by a therapy-free interval of 7&ndash;9 days for bone marrow recovery; thereafter, consolidation cycles (often shortened) can be performed until remission or occurrence of toxicity. Or the treatment can be continued until bone marrow hypoplasia, which is considered to be a tolerance limit.</p><p>&nbsp;</p><p>Prior to the repetition of a treatment cycle (often shortened), a treatment-free interval of at least 14 days or until recovery of the bone marrow must be observed.</p><p>&nbsp;</p><p>b)<em>&nbsp;&nbsp;&nbsp; </em><u>Maintenance Therapy in Case of Leukaemia</u></p><p>The maintenance dose and administration depend on the treatment regimen used.</p><p>Doses of 75&ndash;100 mg/m&sup2; BSA/day once a month on 5 consecutive days or once a week have been administered.</p><p><em>&nbsp;</em></p><p>c)<em>&nbsp;&nbsp;&nbsp; </em><u>CNS Infection</u></p><p>10&ndash;30 mg/m&sup2; BSA/day three times weekly intrathecally</p><p><em>&nbsp;</em></p><p>d)<em>&nbsp;&nbsp;&nbsp; </em><u>Lymphoma</u></p><p>This disease is generally treated with a suitable combination therapy.</p><p><u>&nbsp;</u></p><p><u>High Dosage Therapy</u></p><p>Unless specified otherwise, the dose is 4&ndash;12 times 2&ndash;3 g/m&sup2; BSA every 12 hours. The entire treatment dose must not exceed 36 g/m&sup2; BSA.</p><p>&nbsp;</p><p>Total dose and time duration must be specified by the treating physician. Depending on the number of infusions, the treatment cycle can be repeated after the recovery of the bone marrow.</p><p>&nbsp;</p><p><strong>Method of Administration</strong></p><p>For IV Continuous drip infusion, for intravenous and intrathecal or subcutaneous use.</p><p><u>&nbsp;</u></p><p><u>1) In case of standard therapy</u></p><p>Alexan can be administered as follows:</p><p>continuous IV infusion, IV injection, intrathecal injection or as an exception, subcutaneous injection.</p><p>&nbsp;</p><p>In the case of intravenous injection, a minimal therapeutic plasma concentration is undershot in less than one hour in most patients due to the short half-life of cytarabine. Therefore, distribution of the daily dose into two or more doses at equal intervals is necessary. Physiological saline solution or 5% glucose solution can be used to produce an Alexan solution for infusion. Data for the duration of long-term infusions ranges from 8&ndash;12 hours to 120&ndash;168 hours. Compared to a single IV injection, equal doses exhibit more pronounced gastrointestinal intolerance via continuous drip infusion.</p><p>&nbsp;</p><p>With intrathecal administration, it is recommended to collect 5&ndash;8 ml liquor, mix with the injection solution in the syringe and inject slowly. Systemic toxicity is not expected in this type of application. Subcutaneous injection is only performed in exceptional cases and only used in maintenance therapy. Intracutaneous injection must be avoided due to the risk of oedema.</p><p>&nbsp;</p><p><u>2) In case of high dosage therapy</u></p><p>Alexan is administered as a 1- to 3-hour intravenous infusion.</p><p>If perfusors are used, Alexan can also be used undiluted.</p><p>Physiological saline solution or 5% glucose solution can be used to produce a diluted solution for infusion.</p><p>All Alexan preparations are compatible with each other and can be combined to produce the individually stipulated dose. As a result, no residual quantities of the medicinal product are produced.</p><p>&nbsp;</p><p>Note: The use of solvents containing preservatives must be avoided. This applies in particular for intrathecal use or in the case of high dosage therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	-	Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1
-	Patients with preexisting bone marrow suppression must be excluded from treatment
-	Severely reduced hepatic and/or renal function, existing severe infections, gastro and peptic ulcers and recent surgery
-	Anaemia/erythrocytopaenia, leukopaenia and/or thrombocytopaenia of non-malignant aetiology (e.g. bone marrow aplasia); unless the treating physician deems treatment with Alexan to be the most likely alternative for the patient
-	Breastfeeding (see Section 4.6).
-	Alexan may not be used together with or within 4 weeks after treatment with brivudine, sorivudine and analogues. Brivudine, sorivudine and analogues are potent inhibitors of the 5-FU-decomposing enzyme dihydropyrimidine dehydrogenase (DPD) (see also Sections 4.4 and 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytarabine should be used with caution in specialised oncological facilities with corresponding means for regular monitoring of clinical biochemical and haematological effects during and after administration. The usual precautionary measures must be observed when handling the vials (protective goggles, gloves, mouth, nose protection, if possible, air extraction). In particular, care must be taken that facilities are available to monitor the effects on patients and to take countermeasures, if necessary.</p><p>&nbsp;</p><p><u>Haematological Effects</u></p><p>Cytarabine has a strong myelosuppressive effect. In patients with a history of bone marrow depression, the treatment should be initiated with caution.</p><p>Patients who are administered this medicine must be closely monitored. In addition, leukocyte and platelet counts should be determined daily at the start of treatment. In general, leukocyte and platelet counts should be determined as frequently as possible and monitored regularly after the end of therapy. This also applies to intrathecal use.</p><p>If drug-induced bone marrow depression has produced a platelet count &lt;50,000 or a polymorphonuclear count &lt;1,000/mm<sup>3</sup>, the therapy must be interrupted or modified. The number of formed elements in peripheral blood can continue to fall after administration of the medicinal product has ended and will reach its lowest value after a drug-free interval of 5-7 days. If indicated, the therapy should be resumed if clear signs of a recovery in bone marrow function are detectable (in consecutive examinations of the bone marrow). The inspection may be omitted in patients who do not continue receiving the medicinal product until &lsquo;normal&rsquo; peripheral blood values have been achieved.</p><p>&nbsp;</p><p>Bone marrow examinations should be performed regularly once no more blasts are found in the peripheral blood.</p><p>&nbsp;</p><p>Arrangements for the treatment of potentially fatal complications of bone marrow depression (infections due to granulocytopaenia and other disturbed defence mechanisms, secondary haemorrhage due to thrombocytopaenia) should be available.</p><p>&nbsp;</p><p><u>Tumour Lysis Syndrome</u></p><p>As with other cytostatics, cytarabine may induce hyperuricaemia as a consequence of rapid lysis of neoplastic cells. The doctor should monitor uric acid content in the blood and be prepared to employ supportive and pharmacological measures, which may be necessary to control any complications.</p><p>Hyperuricaemia prophylaxis is recommended in patients with high blast counts or extensive tumour masses (non-Hodgkin&rsquo;s lymphoma). Arrangements for supportive measures should be available.</p><p><u>&nbsp;</u></p><p>Reduced hepatic and/or renal function is considered a predisposing factor for increased CNS toxicity from cytarabine.</p><p>&nbsp;</p><p>Anaphylactic reactions have occurred during cytarabine therapy. Anaphylaxis that led to acute cardiac arrest and required resuscitation was reported. This occurred immediately after the intravenous administration of cytarabine (see Section 4.8).</p><p>&nbsp;</p><p><u>High Dosage Therapy</u></p><p>The risk of CNS adverse effects is greater in patients who have been previously treated with intrathecal chemotherapy or radiotherapy due to a CNS disease.</p><p>&nbsp;</p><p>In patients with acute, non-lymphatic leukaemia, peripheral motor and sensory neuropathy occurred after consolidation of high dosage cytarabine, daunorubicin and asparaginase therapy. Patients being treated with high cytarabine doses should be examined for neuropathies as dosage changes may be necessary to avoid irreversible neurological disorders.</p><p>&nbsp;</p><p>After certain experimental high dosage regimens (2&ndash;3 g/m<sup>2</sup>) containing cytarabine, severe and occasionally fatal toxicity of the central nervous system, gastrointestinal tract and lungs (different from the conventional treatment regimen with cytarabine) was reported. These reactions included reversible corneal toxicity among others; cerebral and cerebellar functional disorders, usually reversible; somnolence; seizures; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis, leading to peritonitis; sepsis and liver abscess; as well as adult respiratory distress syndrome (ARDS) and pulmonary oedema (see Section 4.8).</p><p>&nbsp;</p><p>Cytarabine has been proven to be mutagenic and carcinogenic in animals. The possibility of a similar effect should be considered in the long-term management of the patient.</p><p>&nbsp;</p><p>If intravenous doses are administered quickly, patients often suffer from nausea and vomiting can occur over several hours following administration. This problem is less pronounced when the drug is infused.</p><p>&nbsp;</p><p><u>Conventional Dosage Regimen</u></p><p>In patients treated with conventional cytarabine doses in combination with other medicinal products, pressure sensitivity of the abdomen (peritonitis) and guaiac-positive colitis with neutropaenia and thrombocytopaenia were reported. These patients responded to non-surgical medical treatment.</p><p>&nbsp;</p><p>In children with AML, delayed progressive, ascending and fatal paralysis has been reported after intrathecal and intravenous administration of conventional cytarabine doses in combination with other medicinal products.</p><p>&nbsp;</p><p><em>Renal and Hepatic Function:</em></p><p>Both hepatic and renal function should be monitored during cytarabine therapy. Special caution is required with mild reduction of hepatic and renal function.</p><p>Periodic examinations of bone marrow, liver and kidney function should be performed in patients receiving cytarabine.</p><p>&nbsp;</p><p>Since cytarabine is largely metabolised in the liver, a stronger effect from the substance is possible in the case of liver damage. An increase in efficacy also results in reduced renal function. In the case of liver and/or kidney failure, a corresponding dose reduction must be performed while blood levels are being monitored. Particularly patients with reduced liver and/or kidney function have an increased risk of CNS toxicity after treatment with high dosage cytarabine. Regular monitoring of liver and kidney function as well as uric acid levels is necessary. In patients with pre-existing reduced hepatic function, cytarabine should only be used with caution, with reduced dosage levels and after a strict risk-benefit assessment.</p><p>&nbsp;</p><p>After experimental high dosage cytarabine therapies in combination with cyclophosphamide in preparation for bone marrow transplantation, cases of cardiomyopathy and resulting deaths were reported.</p><p>&nbsp;</p><p>Plentiful supply of fluids is indicated.</p><p>&nbsp;</p><p>High dosage cytarabine treatment in patients over 60 years of age may only take place after a particularly careful risk-benefit assessment.</p><p>&nbsp;</p><p><u>Contraceptive Measures</u></p><p>Cytarabine can have mutagenic effects. Men should therefore not father children during treatment and for up to six months after ending treatment. In addition, men should receive information before treatment regarding the option of sperm preservation, since there is the possibility of irreversible infertility after cytarabine therapy.</p><p>&nbsp;</p><p>A genetic consultation is recommended if women wish to have children after the end of treatment.</p><p>&nbsp;</p><p>Severe gastrointestinal adverse effects will require anti-emetics and other supportive measures.</p><p>&nbsp;</p><p>High dosage treatments require regular monitoring of CNS and lung functions by a physician experienced in this type of treatment.</p><p>&nbsp;</p><p>In order to avoid ophthalmological complications, eyes must be rinsed regularly during high dosage treatment.</p><p>&nbsp;</p><p>In the case of severe bone marrow depression, patients should be accommodated in a sterile isolation room during treatment.</p><p>&nbsp;</p><p><u>Immunosuppressant effects/increased susceptibility to infections</u></p><p>In patients who are immunosuppressed due to the administration of chemotherapeutic agents such as cytarabine, the administration of live vaccines can lead to severe or life-threatening infections.</p><p>During therapy with cytarabine, no vaccinations with live vaccines should be performed. Dead or inactivated vaccines may be administered; however, the reaction to these vaccines may be reduced.</p><p>&nbsp;</p><p>In common with other tumour-inhibiting substances, treatment with cytarabine also entails the risk of bleeding complications and severe infections as a result of the bone marrow depression. During high dosage therapy, CNS system disorders, gastrointestinal disorders, reduced hepatic function, skin reactions and eye problems may occur.</p><p>&nbsp;</p><p>In the case of signs of CNS toxicity, similarly if an allergy occurs, a careful risk-benefit assessment should be carried out.</p><p>&nbsp;</p><p>Contact with skin and mucosa, especially in the area of the eyes, should be avoided.</p><p>&nbsp;</p><p>Cytarabine is a teratogenic and mutagenic substance.</p><p>&nbsp;</p><p>The enzyme dihydropyrimidine dehydrogenase (DPD) plays an important role in the decomposition of 5-FU. Nucleoside analogues, such as brivudine and sorivudine may lead to a marked increase in the plasma concentration of 5-FU or other fluoropyrimidines and to increased toxicity as a consequence.</p><p>&nbsp;</p><p>Furthermore, an interval of at least 4 weeks must be observed between the use of Alexan and brivudine, sorivudine and analogues.</p><p>&nbsp;</p><p>If necessary, the determination of the DPD enzyme activity is indicated before starting treatment with Alexan. In the event of the accidental administration of brivudine to patients who are being treated with Alexan, effective measures should be taken to reduce fluorouracil toxicity. Immediate admission to a hospital is recommended. All measures for preventing systemic infections and dehydration should be initiated.</p><p>&nbsp;</p><p>Patients who are taking phenytoin simultaneously with Alexan should be regularly examined for potentially elevated phenytoin plasma levels.</p><p>&nbsp;</p><p><u>Pancreatitis</u></p><p>Cases of pancreatitis were observed with the use of cytarabine.</p><p>&nbsp;</p><p><u>Neurology</u></p><p>Cases of severe neurological side effects that ranged from headache to paralysis, coma, and stroke-like episodes were mainly observed in children and adolescents who received intravenous cytarabine in combination with intrathecal methotrexate.</p><p>&nbsp;</p><p><u>Children and Adolescents</u></p><p>Safety in infants has not been proven.</p><p>&nbsp;</p><p><strong>Alexan contains sodium:</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, i.e. it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the case of previous therapy with <u>L-asparaginase</u>, acute pancreatitis can occur with cytarabine.</p><p>&nbsp;</p><p>Myelotoxic interactions with other treatment methods that have a toxic effect on bone marrow (in particular other cytostatics and radiotherapy) must be expected corresponding to the respective co-medication.</p><p>&nbsp;</p><p><u>5-Fluorocytosine</u></p><p>5-fluorocytosine should not be co-administered with cytarabine, as it has been shown that the therapeutic effect of 5-fluorocytosine is reversed during such treatment. Limited data suggests that cytarabine may antagonise the anti-infective effect of 5-fluorocytosin, possibly by competitively inhibiting anti-infective absorption through fungi.</p><p>&nbsp;</p><p><u>Cardiac Glycosides</u></p><p>Gastrointestinal absorption of oral digoxin tablets can be significantly reduced in patients receiving combination chemotherapy (including therapies with cytarabine), as a consequence of temporary damage to the intestinal mucosa by cytostatics.</p><p>In patients who received beta-acetyldigoxin and chemotherapeutic treatment with cyclophosphamides, vincristine and prednisone with or without cytarabine or procarbazine, there was a reversible reduction in steady state digoxin level and reduced renal glycoside elimination.</p><p>Limited data suggest that the extent of the gastrointestinal absorption of digitoxin is not impacted significantly by concomitant administration of combination chemotherapy therapies known to reduce the absorption of digoxin. Therefore, monitoring of the plasma digoxin level may be indicated in patients receiving similar chemotherapeutic combination treatments. Use of <u>digitoxin</u> may be considered as an alternative in these patients.</p><p>&nbsp;</p><p><u>Anti-Infective agents</u></p><p>An <em>in-vitro</em> interaction study between <u>gentamicin</u> and cytarabine showed cytarabine-related antagonism with regard to the sensitivity of <em>K. pneumoniae</em>-strains. In patients receiving cytarabine and being treated with gentamicin for a <em>K. pneumoniae</em> infection, the absence of immediate response to gentamicin may necessitate reevaluation of the antibacterial therapy.</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Intravenous cytarabine administered simultaneously with intrathecal <u>methotrexate</u> can increase the risk of severe neurological adverse effects such as headache, paralysis, coma and stroke-like episodes (see Section 4.4).</p><p>&nbsp;</p><p>Furthermore, an interval of at least 4 weeks must be observed between the use of Alexan and <u>brivudine, sorivudine and analogues</u>.</p><p>If necessary, the determination of the DPD enzyme activity is indicated before starting treatment with Alexan.</p><p>&nbsp;</p><p>In concomitant administration of <u>phenytoin</u> and Alexan, there were reports of an increase in plasma concentrations of phenytoin, which led to symptoms of phenytoin intoxication. (See also Section 4.4)</p><p>&nbsp;</p><p>Cytarabine can interfere with the determination of the protein portion in cerebrospinal fluid by means of turbidimetry (turbidity measurement) or the Folin-Ciocalteu method.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>During pregnancy, Alexan must be administered with particularly strict indication, with careful consideration of the benefit for the mother versus the risk for the foetus.</p><p>&nbsp;</p><p>As cytarabine has a mutagenic and teratogenic effect in some animal species, the possibility of pregnancy must be excluded. The use of cytarabine in women who are pregnant or could become pregnant is only to be carried out after careful consideration of the possible benefits and risks.</p><p>&nbsp;</p><p>Due to the potential for anomalies in cytotoxic therapy, especially during the first trimester, a patient who is pregnant during treatment with cytarabine should be informed about the potential risk for the foetus and the advisability of continuing the pregnancy. There is a clear, but significantly reduced risk when the therapy is started in the second or third trimester. Although normal infants have been born to patients who received treatment in all three trimesters of pregnancy, follow-up care for such infants would be advisable.</p><p>&nbsp;</p><p>Adequate contraception must be ensured for both male and female patients of fertile age during treatment with Alexan and for up to 6 months thereafter.</p><p>&nbsp;</p><p>If a pregnancy occurs during Alexan therapy, genetic consultation must be carried out (see Section 5.3).</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Cytarabine must not be used during breastfeeding.</p><p>&nbsp;</p><p>Breastfeeding must be stopped on initiation of treatment with Alexan.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No fertility studies evaluating the reproductive toxicity of cytarabine have been performed. In patients receiving cytarabine (especially in combination with alkylating agents), gonadal suppression leading to amenorrhoea or azoospermia may occur. In general, these effects appear to be related to the dosage and duration of treatment and irreversible (see Section 4.8). Since cytarabine has mutagenic potential that can lead to chromosomal damage in human spermatozoa, men who are treated with cytarabine must be instructed to take reliable contraceptive measures. Men must not father children during treatment and for up to six months after ending treatment. In addition, men should receive information before treatment regarding the option of sperm preservation, since there is the possibility of irreversible infertility after cytarabine therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cytarabine has no influence on the ability to drive a vehicle and operate machines. However, in patients receiving chemotherapy, the ability to drive a vehicle or operate machines may be impaired due to adverse effects. Patients should be informed and instructed to avoid such activities if possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The undesirable effects caused by cytarabine are dependent on dosage, method of administration and duration of treatment.</p><p>&nbsp;</p><p>Gastrointestinal adverse effects are the most common. Cytarabine has a toxic effect on bone marrow and causes adverse haemorrhagic effects.</p><p>&nbsp;</p><p>Blood and Lymphatic System Disorders: As cytarabine has a myelosuppressive effect, anaemia, leukopaenia, thrombocytopaenia, megaloblastosis and reticulocyte reduction are to be expected as a consequence of the administration of the medication. The severity of these reactions is dependent on dose and therapy regimen. Morphological cell changes in the bone marrow and peripheral blood count are to be expected.</p><p>&nbsp;</p><p>Cytarabine syndrome has been described. It is characterised by fever, myalgia, bone pain, isolated chest pains, maculopapular rash, conjunctivitis and malaise. It usually occurs 6&ndash;12 hours after the administration of the medication.</p><p>Corticosteroids have proven to be of use in the treatment or prevention of this syndrome. If the symptoms are severe enough to justify treatment, both corticosteroids and the continuation of cytarabine therapy should be considered.</p><p>&nbsp;</p><p>The evaluation of adverse reactions is based on the following frequencies:</p><p>&nbsp;</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100, &lt;1/10)</p><p>Uncommon (&ge;1/1,000, &lt;1/100)</p><p>Rare (&ge;1/10,000, &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Unknown (frequency cannot be estimated from the available data)</p><p><em>&nbsp;</em></p><p><strong><em><u>Infections and Parasitic Diseases</u></em></strong></p><p>Viral, bacterial, fungal, parasitic or saprophytic infections throughout the whole body can be associated with the use of cytarabine alone or in combination with other immunosuppressive substances (at immunosuppressive doses that affect cellular or humoral immunity). These infections can be mild, but can also be severe and sometimes fatal.</p><p><em>&nbsp;</em></p><p><em>Very common: </em></p><p>Sepsis (immunosuppression), pneumonia, infection</p><p><em>&nbsp;</em></p><p><em>Not known:</em></p><p>Injection site cellulitis, liver abscess</p><p>&nbsp;</p><p><strong><em><u>Blood and Lymphatic System Disorders</u></em></strong></p><p><em>Very common:</em></p><p>Myelosuppression, blood count changes (leukopaenia, thrombocytopaenia, anaemia, megaloblastosis, reticulocytopaenia); occur in a dosage-dependent manner.</p><p>At conventional dosage, leukopaenia occurs with trough values on days 12 to 24.</p><p>High dosage therapy is associated with considerable myelotoxicity.</p><p>&nbsp;</p><p><strong><em><u>Metabolism and Nutritional Disorders</u></em></strong></p><p><em>Common:</em></p><p>Anorexia, hyperuricaemia as a consequence of rapid lysis of neoplastic cells</p><p>As with all cytostatics, the use of cytarabine can lead to hypocalcaemia and, as a result of cell disintegration, secondary hyperuricaemia, which may necessitate corresponding countermeasures.</p><p>&nbsp;</p><p><strong><em><u>Nervous System Disorders</u></em></strong></p><p>Central nervous system disorders are observed primarily in high dosage therapy.</p><p>At total doses below 36 g cytarabine/m<sup>2</sup> body surface area, toxic CNS reactions are rare. Disposing factors are old age, hepatic and renal insufficiency, previous CNS treatment (irradiation, intrathecal cytostatic applications) and alcohol abuse.</p><p>Central nervous system disorders are usually reversible.</p><p><em>&nbsp;</em></p><p><em>Common:</em></p><p>Cerebral/cerebellar disorders (nystagmus, dysarthria, ataxia, confusion and personality changes), thought and movement pattern disorder, somnolence, lethargy, coma, tremor, seizures and anorexia</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Peripheral neuropathy</p><p><em>&nbsp;</em></p><p><em>Rare:</em></p><p>Intrathecal use of cytarabine can lead to nausea, vomiting, fever and/or other symptoms of arachnoiditis. These phenomena can also be the consequence of a lumbar puncture. The symptoms are often mild and reversible. Intrathecal administration of cytarabine at doses above 30 mg/m<sup>2</sup> BSA often leads to neurotoxic reactions. In particular, short dosing intervals can lead to cumulative neurotoxicity (see also Section 4.2)</p><p><em>&nbsp;</em></p><p><em>Very rare:</em></p><p>Isolated cases of necrotising leukoencephalopathy, myelopathy culminating in paraplegia or quadriplegia as well as loss of vision have been described after intrathecal administration of cytarabine. Intrathecal application of benzyl alcohol or other solution-mediated additives should absolutely be avoided.</p><p>&nbsp;</p><p><em>Not known: </em></p><p>Neurotoxicity, dizziness, headaches, neuritis and - after high doses - individual cases of peripheral nerve lesions have been described, as well as cases of delayed progressive ascending paralysis, meningitis and encephalitis.</p><p><em>&nbsp;</em></p><p><strong><em><u>Eye Disorders</u></em></strong></p><p><em>Very common:</em></p><p>Conjunctivitis (in the case of high dosage therapy)</p><p>&nbsp;</p><p><em>Common:</em></p><p>Conjunctivitis, keratitis, photophobia, burning eyes, severe lacrimation and vision disorders are dose-dependent and were observed in 25 to 80% of patients under high dosage therapy.</p><p>Reversible, haemorrhagic conjunctivitis (photophobia, burning, vision disorders, increased lacrimation), ulcerative keratitis.</p><p>By frequent rinsing of the eyes or the prophylactic use of corticosteroid eyedrops, the symptoms can be prevented or mitigated.</p><p><em>&nbsp;</em></p><p><strong><em><u>Cardiac Disorders</u></em></strong></p><p><em>Uncommon:</em></p><p>Acute pericarditis</p><p><em>&nbsp;</em></p><p><em>Very rare:</em></p><p>Myocardial damage, transient cardiac arrhythmias<em> </em></p><p><em>&nbsp;</em></p><p><em>Not known:</em></p><p>Sinus bradycardia</p><p><em>&nbsp;</em></p><p><strong><em><u>Respiratory, Thoracic and Mediastinal Disorders</u></em></strong></p><p><em>Uncommon:</em></p><p>Dyspnoea, sore throat</p><p>Pulmonary oedema due to increased permeability of the alveolar capillaries was uncommon at conventional doses, and was observed in approx. 10 to 30% of patients after high cytarabine doses. These pulmonary complications are usually reversible. Respiratory complaints, pneumonia and pulmonary toxicity occurred.</p><p>&nbsp;</p><p>Patients receiving average doses (1 g cytarabine/m<sup>2</sup> BSA) and other concomitant cytostatics developed diffuse interstitial pneumonia in 10 of 52 cases. However, no confirmed causal connection with the use of cytarabine could be found.</p><p><em>&nbsp;</em></p><p><strong><em><u>Gastrointestinal Disorders</u></em></strong></p><p><em>Common:</em></p><p>Abdominal pain, diarrhoea, dysphagia, mucositis, mucosal ulcerations (oral, anal) especially in high dosage treatment; severe diarrhoea with corresponding potassium and protein depletion, nausea and vomiting (especially after rapid intravenous injection)</p><p><em>&nbsp;</em></p><p><em>Uncommon:</em></p><p>Oesophagitis, oesophageal ulcerations, severe changes in the gastrointestinal mucosa with ulcerations, abdominal wall emphysema and infections can occur. This can lead to intestinal necrosis and necrotising colitis.</p><p>Particularly with high dose therapy, cystoid pneumatoses and intestinal necrosis with ileus and peritonitis are an uncommonly reported occurrence.</p><p>&nbsp;</p><p><em>Very rare:</em></p><p>Pancreatitis</p><p>&nbsp;</p><p><strong><em><u>Hepatobiliary Disorders</u></em></strong></p><p><em>Very common:</em></p><p>Reduced hepatic function with elevated cholestasis-indicating enzymes and hyperbilirubinaemia were observed in 25 to 50% of patients receiving high dosage treatment.</p><p><em>&nbsp;</em></p><p><em>Very rare:</em></p><p>Hepatomegaly</p><p>Individual reports exist of the occurrence of hepatic vein thrombosis (Budd-Chiari syndrome).</p><p>&nbsp;</p><p><em>Not known:</em></p><p>Jaundice</p><p><em>&nbsp;</em></p><p><strong><em><u>Skin and subcutaneous tissue disorders</u></em></strong></p><p><em>Very common:</em></p><p>Rash</p><p><em>&nbsp;</em></p><p><em>Common:</em></p><p>Reversible adverse skin reactions such as maculopapular exanthema, ulceration, erythroderma, erythema, urticaria, vasculitis, mottled skin and pruritus.</p><p>Exfoliative dermatitis and alopecia may occur after high doses.</p><p>&nbsp;</p><p>After high dosage cytarabine, up to 75% of patients develop generalised erythema, including blistering and desquamation.</p><p>&nbsp;</p><p><em>Uncommon:</em></p><p>Lentigo, skin ulceration, pruritus, burning pain on the palms of the hands and soles of the feet</p><p>&nbsp;</p><p><em>Very rare:</em></p><p>Neutrophilic eccrine hidradenitis</p><p>&nbsp;</p><p><em>Not known:</em></p><p>palmar-plantar erythrodysaesthesia</p><p>&nbsp;</p><p><strong><em><u>Musculoskeletal, connective tissue and bone disorders</u></em></strong></p><p><em>Uncommon:</em></p><p>Myalgia and/or arthralgia have been observed after high doses of cytarabine</p><p><em>&nbsp;</em></p><p><em>Very rare:</em></p><p>The occurrence of rhabdomyolysis has been described.</p><p>&nbsp;</p><p><strong><em><u>Renal and Urinary Disorders</u></em></strong></p><p><em>Common:</em></p><p>Urinary disorders, reduced renal function</p><p>&nbsp;</p><p>An increase in plasma creatinine has been observed in 5% to 20% of patients receiving high dosage cytarabine therapy, but a confirmed causal connection with cytarabine has not been proven.</p><p>&nbsp;</p><p>Measures to prevent uric acid nephropathy should be taken in the case of massive cell degeneration.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>General Disorders and Complaints in the Area of Administration</u></em></strong></p><p><em>Common:</em></p><p>Throat inflammation, allergic oedema, gonadal dysfunction, chest pain, ascites, immunosuppression, sepsis, thrombophlebitis and haemorrhage, thrombophlebitis at the injection site</p><p>Fever occurs in 20%&ndash;50% of patients receiving high dosage therapy.</p><p>&nbsp;</p><p><em>Very rare:</em></p><p>Allergic reactions (urticaria, anaphylaxis) of the immediate type are very rare. One case of anaphylaxis was reported, which led to a cardiopulmonary arrest and required resuscitation measures. This occurred immediately after IV- administration of cytarabine.</p><p>The syndrome of inappropriate antidiuretic hormone secretion was observed in individual cases in patients receiving high dosage treatment with cytarabine.</p><p>&nbsp;</p><p><u>Cytarabine (Ara-C) Syndrome</u></p><p>The syndrome described in the literature is characterised by fever, myalgia, bone pain, occasionally chest pain, maculopapular exanthema, conjunctivitis and nausea. It generally occurs 6&ndash;12 hours after administration. Corticosteroids have been proven in the treatment or prevention of the syndrome. If corticosteroids are effective in this regard, continuation of therapy with cytarabine may be considered.</p><p>&nbsp;</p><p><strong>Adverse effects with high dosage cytarabine therapy, which were not observed at conventional dosages:</strong></p><p><u>Haematological Toxicity</u></p><p>Expressed as profound pancytopaenia, which lasts for 15-25 days associated with more pronounced bone marrow aplasia than observed at conventional doses.</p><p>&nbsp;</p><p><u>Nervous System Disorders</u></p><p>After treatment with high doses of cytarabine, 3-37% of patients experienced cerebral or cerebellar symptoms such as personality changes, impaired attention, dysarthria, ataxia, tremor, nystagmus, headaches, confusion, sleepiness, dizziness, coma, seizures. The incidence may be higher in elderly patients (&gt;55 years). Other pre-disposing factors are reduced hepatic and/or renal function, previous CNS treatment (e.g. radiotherapy) and alcohol abuse. CNS disorders are reversible in most cases.</p><p>&nbsp;</p><p>The risk of CNS toxicity is increased if cytarabine treatment (high dose administered IV) is combined with another CNS toxic therapy such as radiotherapy or high dosage therapy.</p><p>&nbsp;</p><p><u>Corneal and Conjunctival Toxicity</u></p><p>Reversible lesions of the cornea and haemorrhagic conjunctivitis were described. These can be prevented or reduced by administering eyedrops containing corticosteroids.</p><p>&nbsp;</p><p><u>Gastrointestinal Disorders</u></p><p>Particularly with high dosage treatment with cytarabine, severe reactions may occur in addition to common symptoms. Intestinal perforation, pneumatosis cystoides intestinalis or necrosis with ileus and peritonitis have been reported.</p><p>&nbsp;</p><p>Liver abscesses, Budd-Chiari syndrome (hepatic vein thrombosis) and pancreatitis have been reported after high dosage therapy.</p><p>&nbsp;</p><p><u>Respiratory, Thoracic and Mediastinal Disorders</u></p><p>Clinical signs such as pulmonary oedema/ARDS can develop, especially with high dosage therapy. This reaction is presumably caused by an injury to the alveolar capillaries. Determination of frequency is difficult (indicated in various publications to be 10-26%), since patients were usually in relapse and other factors may have contributed to this reaction.</p><p>&nbsp;</p><p><u>Miscellaneous</u></p><p>Cardiomyopathy and rhabdomyolysis have been reported after cytarabine therapy. One case of anaphylaxis has been reported, which led to cardiac arrest and required resuscitation. This case occurred directly after intravenous administration of cytarabine.</p><p>&nbsp;</p><p>Gastrointestinal side effects are reduced if cytarabine is administered as a infusion. Local glucocorticoids are recommended to prevent haemorrhagic conjunctivitis.</p><p>&nbsp;</p><p>Amenorrhoea and azoospermia (see Section 4.6).</p><p>&nbsp;</p><p><strong>The following adverse effects have been observed with intrathecal application:</strong></p><p>Expected Systemic Reactions: Bone marrow depression, nausea, vomiting. Severe spinal toxicity, which has even led to quadriplegia and paralysis, necrotising encephalopathy, blindness and other isolated neurotoxicities has been reported occasionally.</p><p>&nbsp;</p><p>With high dosage continuous infusion (more than 200 mg/m&sup2; BSA/day over 5&ndash;7 days), the adverse effects are more pronounced than in standard therapy.</p><p>&nbsp;</p><p>Polyserositis and early deaths have occurred as a result of non-controllable haemorrhage or septicaemia as well as fatalities as a result of prolonged bone marrow depression. 4.5 g/m&sup2; has been determined as the maximum tolerable dose in humans. At doses above 3 g/m&sup2;, cerebral toxicity is significantly more pronounced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms of Intoxication</u></p><p>Chronic overdose may lead to severe bone marrow depression, including massive haemorrhage and life-threatening infections and neurotoxicity.</p><p>&nbsp;</p><p>Cytarabine myelotoxicity is dosage-limiting. Even in the context of high dosage treatment at cumulative doses of approx. 18 to 36 g cytarabine per treatment cycle, severe bone marrow toxicity culminating in myelophthisis, which is clinically only detectable at its full extent after 1 to 2 weeks, must be expected. It is dependent both on the dosage and other factors such as the patient&rsquo;s age, clinical condition and bone marrow reserves as well as additional myelotoxic therapy.</p><p>&nbsp;</p><p>Twelve doses of 4.5 g/m<sup>2</sup> administered with intravenous infusion over an hour, every 12 hours led to irreversible and fatal CNS toxicity.</p><p>&nbsp;</p><p><u>Treatment of Intoxication</u></p><p>No specific antidote to cytarabine is known.</p><p>If intoxication occurs, immediate discontinuation of cytarabine therapy and careful monitoring of the patient is required.</p><p>Accidental severe overdose during intrathecal use requires an immediate exchange of the cerebrospinal fluid with isotonic sodium chloride solution.</p><p>Even if an overdose is merely suspected, close monitoring of the blood count must be performed over a prolonged period.</p><p>Corresponding supportive measures (e.g. blood transfusion or platelet transfusion, antibiotics) should be taken.</p><p>&nbsp;</p><p>Cytarabine may be removed by haemodialysis. However, there is no information on effect in the event of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agent, antimetabolite, pyrimidine analogues</p><p>ATC code: L01BC01</p><p>&nbsp;</p><p>Alexan contains cytarabine (4-amino-1-(&szlig;-D-arabinofuranosyl)-1 H-pyrimidine-2-on), a cytostatic agent from the series of antimetabolites. The body&rsquo;s own pyrimidine nucleosides cytidine and 2&rsquo;-deoxycytidine differ only with regard to the sugar residue (arabinose instead of ribose), so it is a pyrimidine analogue.</p><p>&nbsp;</p><p>The active cytarabine nucleotides inhibit DNA synthesis in the S phase of the cell cycle. As a molecular mechanism of action of this effect, discussions are ongoing regarding the inhibition of cytidine phosphate reductase, the incorporation into DNA and RNA, which leads to a dysfunction of these nucleic acids, as well as the inhibition of DNA polymerase. In particular, viral-induced RNA-dependent DNA polymerase (reverse transcriptase) is strongly inhibited. Its capacity to transfer dormant cells (go-phase) into the proliferation cycle (&lsquo;recruitment&rsquo;), which makes these cells available in the chemotherapeutic effect of cell phase-specific cytostatics, probably also contributes to the cytostatic effect of cytarabine.</p><p>&nbsp;</p><p>The sensitivity of a tissue to cytarabine depends on the ratio of its cytidine deaminase activity to the cytidine kinase activity. In the context of treatment with cytarabine, both a priori-existing and acquired resistance to this cytostatic drug is observed, which is attributed to the ratio of the specified enzymes in the tumour tissue.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After absorption into the cell via the transport mechanism for pyrimidine nucleosides, cytarabine is deaminated on the one hand to the inactive uracil-arabinoside, and on the other hand phosphorylated to active nucleotides (cytarabine mono, di- and triphosphate).</p><p>&nbsp;</p><p>The pharmacokinetic properties of cytarabine are determined by the high water or low lipid solubility. The pharmaceutical must be administered parenterally. After an initial distribution phase, the plasma level decreases with a half-life of 2&ndash;2.5 hours. In this second elimination phase, approximately 80% is present in the shape of inactive uracil arabinoside. Within 24 hours, 80% of the administered dose is excreted in the urine, predominantly in the shape of uracil-arabinoside. In cerebrospinal fluid, the concentrations of cytarabine following IV administration are generally 40% of that of the blood plasma. In intrathecal administration, cytarabine levels in the cerebrospinal fluid decrease with a half-life of 2&ndash;11 hours, whereby largely unchanged cytarabine is present in the cerebrospinal fluid due to the low deaminase activity.</p><p>&nbsp;</p><p>The kinetics of the blood levels of cytarabine remain constant even after repeated administration and are not influenced by corticosteroids and other cytostatics.</p><p>&nbsp;</p><p>Constant, dosage-dependent blood levels are achieved after 30&ndash;60 minutes in the case of an IV infusion.</p><p>&nbsp;</p><p>Following subcutaneous administration, peak plasma concentrations are reached after approx. 20&ndash;60 minutes. With comparable dosage, they are clearly below the plasma levels that can be achieved after IV administration.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><em>a) Subchronic and Chronic Toxicity</em></p><p>During animal testing, mainly bone marrow depression with blood count changes and damage to the intestinal mucosa were observed in subchronic toxicity.</p><p>&nbsp;</p><p>There are no studies into chronic toxicity from cytarabine.</p><p>&nbsp;</p><p><em>b) Mutagenic and Tumorigenic Potential:</em></p><p>Cytarabine is mutagenic in the animal model. In humans, chromosomal defects occurred in peripheral lymphocytes after cytarabine treatment.</p><p>It was shown that cytarabine is carcinogenic in animals. The possibility of a similar effect in humans should be considered in planning long-term therapy.</p><p><em>&nbsp;</em></p><p><em>c) Reproductive Toxicity</em></p><p>Cytarabine showed teratogenic effect in various animal species. Abnormalities of the skeleton, eyes, brain and kidneys were observed. Data available for humans is insufficient. The previously observed malformations were in the extremities, the outer ear and the auditory canal. Exposure in the third trimester of pregnancy can lead or contribute to a delay in growth and pancytopaenia in the foetus/neonates.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium lactate solution 60%</p><p>Lactic acid</p><p>Water for injection purposes.</p><p>&nbsp;</p><p><em>Only for 20 mg/ml:</em></p><p>Sodium chloride</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In injection or infusion solutions, cytarabine is incompatible with 5-fluorouracil, heparin, gentamicin, insulin, methotrexate, methylprednisolone, nafcillin, oxacillin and penicillin G. As additional incompatibilities are possible, mixing the medicinal product with other pharmaceuticals is generally inadvisable.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in Section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years

For single use only. Dispose of any unused product.

Solution for infusion after dilution

The chemical and physical stability of the reconstituted preparation when diluted with 0.9% sodi-um chloride has been demonstrated at 2°C to 8°C for 28 days.

From a microbiological point of view, the reconstituted preparation should be used immediately. If the reconstituted preparation is not used immediately, the user is responsible for the duration and conditions of storage. If the ready-to-use solution is not prepared under controlled and vali-dated aseptic conditions, it should not be stored for longer than 24 hours at 2°C to 8°C.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Store in the original packaging in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>For 20 mg/ml:</em></p><p>1/5/10/30 x 2 ml vials</p><p>1/5/10 x 5 ml vials</p><p>&nbsp;</p><p><em>For 50 mg/ml:</em></p><p>1/5/10 x 10 ml vials</p><p>1/5/10 x 20 ml vials</p><p>1/5/10 x 40 ml vials</p><p><em>&nbsp;</em></p><p>Glass vials (type 1) with halobutyl rubber stoppers and with/without transparent plastic containers (ONCO-Safe)</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To prepare an infusion, Alexan can be diluted with physiological saline solution or 5% glucose solution.</p><p>&nbsp;</p><p>If Alexan comes into contact with skin, the affected area should be rinsed with plenty of water and then washed thoroughly with water and soap. If the solution enters the eye, rinse the eye very carefully with plenty of water and then immediately consult an eye specialist.</p><p>&nbsp;</p><p>Pregnant personnel must not come into contact with this medicinal product.</p><p>&nbsp;</p><p>Alexan should not be used after the expiry date.</p><p>&nbsp;</p><p>After use, dispose of the bottle and injection materials (including gloves) according to the provisions for cytostatics. Any unused product as well as the primary packaging must be disposed of as hazardous waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>